Business
Media
Conferences
Publications
CME/CE
Resources
Subscribe

|Videos|June 27, 2021

Dr. Eure on BPH medications and increased risk of heart failure

Author(s)Urology Times staff

Gregg Eure, MD, FACS, Urology of Virginia, discusses the increased of heart failure associated with medications for the treatment of patients with benign prostatic hyperplasia (BPH). A recently published study showed an increased risk of cardiac failure in men with BPH and exposure to 5-alpha reductase inhibitors and/or α-blockers.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

HoLEP patient selection and the technical error most surgeons make past training

ByAmy E. Krambeck, MD

July 2nd 2026

FDA gives nod to feasibility study of NanoKnife IRE for benign prostatic hyperplasia

ByHannah Clarke

June 18th 2026

Dean Elterman, MD, highlights efficacy and safety data on the Zenflow Prostatic Spring

ByDean Elterman, MD, MSc

June 15th 2026

Kevin Zorn, MD, on selecting among different MIST options for BPH

ByKevin C. Zorn, MD, FRCSC, FACS

June 10th 2026

Nicole L. Miller, MD, FACS, on assessing patients after BPH treatment failure

ByNicole L. Miller, MD, FACS

June 9th 2026

Latest CME

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Trending on Urology Times

Published VAPOR 2 data evaluate water vapor ablation for localized prostate cancer

HoLEP patient selection and the technical error most surgeons make past training

From OR to office: How Break Wave changes urology practice workflow

Treatment Intensification in Metastatic Castration-Sensitive Prostate Cancer

FDA updates in urology: June 2026